Drug Resistance, Neoplasm

• 

  Subject Areas on Research

  • 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. 
  • A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. 
  • A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. 
  • A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. 
  • A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. 
  • A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. 
  • A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. 
  • A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. 
  • A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. 
  • A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. 
  • A genomic approach to identify molecular pathways associated with chemotherapy resistance. 
  • A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. 
  • A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. 
  • A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies. 
  • A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. 
  • A pathway-based approach to identify molecular biomarkers in cancer. 
  • A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. 
  • A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. 
  • A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. 
  • A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. 
  • A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. 
  • A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). 
  • A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. 
  • A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. 
  • A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. 
  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. 
  • Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. 
  • Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. 
  • Activation of the PI3K/Akt pathway and chemotherapeutic resistance. 
  • Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. 
  • Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. 
  • Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. 
  • Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. 
  • Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. 
  • Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. 
  • Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence. 
  • Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. 
  • Advanced Melanoma: Resistance Mechanisms to Current Therapies. 
  • Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. 
  • Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. 
  • Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. 
  • An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. 
  • An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. 
  • An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. 
  • An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. 
  • An integrative approach identified genes associated with drug response in gastric cancer. 
  • An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. 
  • Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. 
  • Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. 
  • Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. 
  • Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. 
  • Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. 
  • Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. 
  • Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 
  • Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells. 
  • Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. 
  • Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. 
  • Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. 
  • BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. 
  • BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. 
  • Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. 
  • Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. 
  • Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. 
  • Biomarkers of response and resistance to antiangiogenic therapy. 
  • Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. 
  • Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. 
  • CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. 
  • CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. 
  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
  • CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. 
  • Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. 
  • Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. 
  • Cell surface GRP78 signaling: An emerging role as a transcriptional modulator in cancer. 
  • Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. 
  • Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. 
  • Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. 
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. 
  • Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. 
  • Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. 
  • Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. 
  • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. 
  • Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. 
  • Common responses of tumors and wounds to hypoxia. 
  • Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. 
  • Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. 
  • Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. 
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. 
  • Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. 
  • Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. 
  • Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. 
  • Copper is required for oncogenic BRAF signalling and tumorigenesis. 
  • Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. 
  • Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. 
  • Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models. 
  • Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). 
  • DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. 
  • DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. 
  • Defeating Cancers' Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer's Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. 
  • Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. 
  • Designing a broad-spectrum integrative approach for cancer prevention and treatment. 
  • Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. 
  • Differential platelet levels affect response to taxane-based therapy in ovarian cancer. 
  • Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. 
  • Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells. 
  • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 
  • Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. 
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. 
  • Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. 
  • Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. 
  • Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma. 
  • Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. 
  • Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. 
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. 
  • E2F1-Mediated Induction of NFYB Attenuates Apoptosis via Joint Regulation of a Pro-Survival Transcriptional Program. 
  • EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. 
  • ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. 
  • Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. 
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 
  • Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. 
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. 
  • Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. 
  • Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. 
  • Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. 
  • Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 
  • Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. 
  • Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. 
  • Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer. 
  • Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. 
  • ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. 
  • Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. 
  • Evaluation of hypertension as a marker of bevacizumab efficacy. 
  • Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. 
  • Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. 
  • Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. 
  • Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. 
  • Exosomes in Pancreatic Cancer: from Early Detection to Treatment. 
  • Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • Expression of the transcription factor STAT-1 alpha in insulinoma cells protects against cytotoxic effects of multiple cytokines. 
  • Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. 
  • Extracellular Vesicles: A Brief Overview and Its Role in Precision Medicine. 
  • Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. 
  • Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib. 
  • Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. 
  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. 
  • Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. 
  • G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. 
  • GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. 
  • GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers. 
  • Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. 
  • Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. 
  • Gene therapy and pancreatic cancer. 
  • Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. 
  • Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. 
  • Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. 
  • Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). 
  • Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. 
  • Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors. 
  • Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models. 
  • Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. 
  • Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. 
  • Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. 
  • HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. 
  • HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer. 
  • Heritable resistance to tyrosine kinase inhibitors. 
  • High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. 
  • Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. 
  • Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. 
  • Hormone refractory prostate cancer: Management and advances. 
  • Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. 
  • Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. 
  • Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? 
  • ISG15 as a novel tumor biomarker for drug sensitivity. 
  • Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). 
  • Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. 
  • Imaging drug resistance with radiolabeled molecules. 
  • Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. 
  • Immunohistochemical characterization of neuroendocrine cells in prostate cancer. 
  • Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. 
  • Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. 
  • Impact of race on survival in men with metastatic hormone-refractory prostate cancer. 
  • Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. 
  • In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. 
  • In vitro repair synthesis of BCNU-induced DNA damage. 
  • In-transit melanoma: the role of alkylating-agent resistance in regional therapy. 
  • Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma. 
  • Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition. 
  • Individual responses to chemotherapy-induced oxidative stress. 
  • Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. 
  • Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. 
  • Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. 
  • Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. 
  • Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. 
  • Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. 
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. 
  • Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. 
  • Innovations in design and delivery of chemotherapy for brain tumors. 
  • Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. 
  • Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. 
  • Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. 
  • Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. 
  • Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. 
  • Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. 
  • Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. 
  • Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). 
  • KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. 
  • Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. 
  • LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. 
  • LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. 
  • Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. 
  • Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. 
  • Lin^- CCR2⁺ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. 
  • Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. 
  • Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. 
  • Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. 
  • Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). 
  • Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. 
  • MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. 
  • MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. 
  • MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. 
  • MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. 
  • MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. 
  • Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. 
  • Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. 
  • Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance. 
  • Mapping the Pathways of Resistance to Targeted Therapies. 
  • Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. 
  • Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. 
  • Melanoma proliferation and chemoresistance controlled by the DEK oncogene. 
  • Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy. 
  • Metabolic rewiring drives resistance to targeted cancer therapy. 
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. 
  • MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. 
  • Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. 
  • Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. 
  • Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. 
  • Mitochondrial DNA-depleted A549 cells are resistant to bleomycin. 
  • Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness. 
  • Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. 
  • Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. 
  • Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. 
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 
  • Modulation of resistance to regional chemotherapy in the extremity melanoma model. 
  • Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. 
  • Molecular Imaging and Precision Medicine in Head and Neck Cancer. 
  • Molecular Mechanisms of Castrate-Resistant Prostate Cancer. 
  • Molecular biologic staging of esophageal cancer. 
  • Molecular determinants for enzalutamide-induced transcription in prostate cancer. 
  • Molecular markers of therapeutic resistance in breast cancer. 
  • Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. 
  • Multidrug resistance in ocular melanoma. 
  • Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). 
  • Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. 
  • Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. 
  • N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. 
  • NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. 
  • NCCN Guidelines Insights: Bone Cancer, Version 2.2017. 
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. 
  • NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. 
  • NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. 
  • Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. 
  • Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery. 
  • Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. 
  • New treatment options in castration-resistant prostate cancer. 
  • Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. 
  • Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. 
  • Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. 
  • Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. 
  • O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines. 
  • O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT). 
  • O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 
  • O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. 
  • Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 
  • Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. 
  • Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. 
  • Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. 
  • Overcoming MCL-1-driven adaptive resistance to targeted therapies. 
  • Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. 
  • Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. 
  • Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. 
  • P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). 
  • PAK1 mediates resistance to PI3K inhibition in lymphomas. 
  • PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. 
  • Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. 
  • Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. 
  • Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. 
  • Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. 
  • Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. 
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. 
  • Personalized treatment of lung cancer. 
  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. 
  • Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. 
  • Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. 
  • Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. 
  • Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. 
  • Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. 
  • Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. 
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. 
  • Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. 
  • Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. 
  • Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. 
  • Phase I study of pazopanib plus TH-302 in advanced solid tumors. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. 
  • Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. 
  • Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. 
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. 
  • Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. 
  • Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). 
  • Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. 
  • Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). 
  • Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. 
  • Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. 
  • Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. 
  • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. 
  • Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. 
  • Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis. 
  • Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. 
  • Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. 
  • Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. 
  • Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. 
  • Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer. 
  • Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases. 
  • Preclinical and Coclinical Studies in Prostate Cancer. 
  • Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals. 
  • Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. 
  • Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. 
  • Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. 
  • Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. 
  • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. 
  • Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. 
  • Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. 
  • Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. 
  • Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. 
  • Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. 
  • Prostate cancer in the late 1990s: hormone refractory disease options. 
  • Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. 
  • Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. 
  • Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. 
  • RAD52 variants predict platinum resistance and prognosis of cervical cancer. 
  • RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. 
  • REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks. 
  • RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. 
  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. 
  • Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. 
  • Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. 
  • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 
  • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. 
  • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. 
  • Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. 
  • Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction? 
  • Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. 
  • Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. 
  • Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. 
  • Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme. 
  • Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. 
  • Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. 
  • Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. 
  • Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. 
  • Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. 
  • Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. 
  • Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. 
  • Resistance to antiplatelet drugs: current status and future research. 
  • Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. 
  • Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. 
  • Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. 
  • Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. 
  • Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. 
  • Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. 
  • Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. 
  • Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha. 
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. 
  • Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. 
  • Role of exosomes in treatment of hepatocellular carcinoma. 
  • Role of transforming growth factor-beta in hematologic malignancies. 
  • SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. 
  • SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. 
  • Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. 
  • Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. 
  • Second-line chemotherapy for advanced hormone-refractory prostate cancer. 
  • Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer. 
  • Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. 
  • Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56δ stabilizes its antiapoptotic activity. 
  • Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. 
  • Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. 
  • Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. 
  • Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors. 
  • Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. 
  • Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. 
  • Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. 
  • Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase. 
  • Starting with the ABCs: Akt in breast cancer. 
  • Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. 
  • Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. 
  • Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma. 
  • Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. 
  • Suberoylanilide hydroxamic acid represses glioma stem-like cells. 
  • Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. 
  • Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. 
  • Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. 
  • Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. 
  • Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. 
  • Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer. 
  • Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. 
  • Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. 
  • Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. 
  • Systematic identification of signaling pathways with potential to confer anticancer drug resistance. 
  • TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance. 
  • Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. 
  • Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. 
  • Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. 
  • Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. 
  • Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. 
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. 
  • The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. 
  • The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. 
  • The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. 
  • The Skp2 Pathway: A Critical Target for Cancer Therapy. 
  • The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines. 
  • The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. 
  • The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. 
  • The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. 
  • The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. 
  • The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. 
  • The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. 
  • The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. 
  • The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. 
  • The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. 
  • Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. 
  • Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. 
  • Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies. 
  • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). 
  • Thioredoxin and hematologic malignancies. 
  • Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. 
  • Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. 
  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 
  • Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. 
  • Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. 
  • Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. 
  • Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. 
  • Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. 
  • Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. 
  • Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. 
  • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. 
  • Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. 
  • Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. 
  • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. 
  • Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. 
  • Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. 
  • Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. 
  • Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. 
  • Wnt Signaling and Drug Resistance in Cancer. 
  • X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. 
  • X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 
  • X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. 
  • [The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer]. 
  • p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. 
  • rHuEPO and improved treatment outcomes: potential modes of action. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering